Noble Life Sciences Hosts Panel Discussion “Vaccinology in the 21st Century: Engineering an Effective Vaccine Platform”
- Andrew Lees, PhD, Scientific Director, Fina BioSolutions
- Peter Pushko, PhD, Chief Scientific Officer, Medigen
- Spencer Stonier, PhD, Director Vaccines Pipeline, Emergent BioSolutions
- Todd Parsley, PhD, Director Infectious Diseases, Noble Life Sciences (Moderator)
With much of the world’s focus on the development of SARS-CoV-2 vaccine, we are bringing an expert panel together to discuss the challenges and strategies for engineering an effective and safe vaccine.
The panelists will share their expertise in vaccine development to discuss topically relevant aspects of vaccinology including:
- Characteristics and challenges in designing an effective vaccine.
- Different vaccine platforms- pros and cons of each.
- How to address adverse vaccine reactions.
- Overcoming pathogen strategies to circumvent the immune response.
- Methods to ensure balancing of the innate and adaptive immune response.
- Strategies to increase immunological durability.
|Andrew Lees, PhDDr. Andrew Lees, founder, and Chief Scientific Officer of Fina BioSolutions, holds over 20 patents and is the author or co-author of more than 60 peer-reviewed papers. He holds a B.S. in Chemistry from Harvey Mudd College and a Ph.D. in Biophysics from The Johns Hopkins University. GlaxoSmithKline, the Serum Institute of India, the Chengdu Institute of Biological Products, and others all use conjugation chemistry (CDAP) developed by Dr. Lees in their S. pneumonia and meningococcal conjugate vaccines.
Dr. Lees is also an associate professor at the University of Maryland School of Medicine’s Center for Vaccine Development, an affiliate at the University of Maryland Bioprocessing Scale-Up Facility, and an adjunct professor in the Department of Medicine at the Uniformed Services University. He teaches protein chromatography through the post-graduate level and is a frequent speaker on conjugation chemistry and biotech entrepreneurship.
Peter Pushko, PhD
Dr. Peter Pushko has over 25 years in molecular biology, virology, and vaccine development. After receiving his Ph.D. degree, Dr. Pushko completed postdoctoral studies at Cambridge University, U.K. and at the U.S. Army Medical Research Institute of Infectious Diseases, Ft. Detrick, MD. He is the author of numerous publications on influenza, alpha-, and filovirus vaccines. Dr. Pushko currently serves as President and Chief Scientific Officer at Medigen, Inc., Frederick, MD (www.medigen-usa.com). His research interests include vaccines for emerging viral diseases including pandemic influenza. Peter has developed live attenuated viruses and virus-like particles (VLP) as vaccine approaches for various viruses.
Spencer Stonier, PhD
Dr. Stonier is a native of rural Upstate New York where he got an undergraduate degree in Biology at the Rochester Institute of Technology (RIT). At RIT, Dr. Stonier developed a fascination with immunology that led him to Houston, TX, where he completed his PhD in Immunology under Kim Schluns, PhD, at the MD Anderson Cancer Center/University of Texas Health Science Center at Houston. Dr. Stonier completed his post-doctoral studies at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) under the mentorship of John Dye, PhD. At USAMRIID, Dr. Stonier investigated various countermeasures against some of the world’s most dangerous pathogens, including Ebola virus as well as other members of the Filoviridae family. Currently, Dr. Stonier is serving as Director of Vaccines Pipeline and Innovation at Emergent BioSolutions where he is dedicated to the scientific evaluation and strategic planning of new projects to support Emergent’s pipeline. He also serves as an integral member of various innovation initiatives across the company.